Article
Allelic Polymorphisms of KIRs and HLAs Predict Favorable Responses to Tyrosine Kinase Inhibitors in CML.
Cancer immunology research - 1 Jun 2018
Ureshino Hiroshi, Shindo Takero, Kojima Hiroto, Kusunoki Yasushi, Miyazaki Yuki, Tanaka Hidenori, Saji Hiroh, Kawaguchi Atsushi, Kimura Shinya
Abstract excerpt
Response to tyrosine kinase inhibitors (TKIs) is variable in chronic myeloid leukemia (CML), and elevated natural killer (NK) cells during TKI therapy are positively correlated with superior outcomes. NK cell function involves interactions of their killer immunoglobulin-like receptors (KIRs) and human leukocyte antigen (HLA) class I on target cells, and the avidity of KIR-HLA interactions depends on the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
